Yes, there is a strong and growing body of literature demonstrating a correlation between **radiomics** (the high-throughput extraction of quantitative features from medical imaging) and **therapeutic resistance patterns** in oncology.

However, while the literature frequently demonstrates **statistical significance** within individual studies, the **consistency** (reproducibility and generalizability) of these correlations across different institutions and scanner types remains the primary challenge in the field.

Here is a breakdown of the current state of the science regarding radiomics and resistance mechanisms.

### 1. The Biological Basis: Why is there a correlation?
The central hypothesis linking radiomics to resistance is **tumor heterogeneity**.
*   **Genotype-Phenotype Link:** Resistance is often driven by specific genetic mutations (e.g., EGFR, KRAS) or the tumor microenvironment (e.g., hypoxia, vascularization).
*   **Imaging Expression:** These microscopic biological properties manifest macroscopically on images. For example, a tumor with high genetic heterogeneity (prone to resistance) often displays high textural entropy (irregularity) on a CT or MRI scan.

### 2. Literature Evidence by Therapy Type
Literature has demonstrated statistically significant correlations in several key areas:

#### A. Targeted Therapy (Genomic Resistance)
*   **NSCLC (Lung Cancer):** This is the most studied area. Research has shown that CT-based radiomic signatures can predict **EGFR** mutation status and **KRAS** mutations.
    *   *Significance:* Tumors with EGFR mutations (sensitive to TKIs) have different texture patterns than wild-type or KRAS-mutated tumors (resistant to EGFR-TKIs).
    *   *Literature:* Studies published in *Radiology* and *Clinical Cancer Research* have reported Area Under the Curve (AUC) values ranging from 0.75 to 0.85 for predicting these mutations non-invasively.

#### B. Chemotherapy (Neoadjuvant Resistance)
*   **Breast Cancer:** MRI radiomics are widely used to predict Pathological Complete Response (pCR) to neoadjuvant chemotherapy.
    *   *Mechanism:* Features related to tumor enhancement kinetics and intratumoral heterogeneity correlate with the tumor's proliferation rate and sensitivity to cytotoxic drugs.
    *   *Literature:* A 2021 meta-analysis in *Nature Scientific Reports* confirmed that radiomics models generally outperform clinical models in predicting response, though validation varies.

#### C. Immunotherapy (Checkpoint Inhibitor Resistance)
*   **Tumor Microenvironment:** Resistance to immunotherapy is often driven by "cold" tumors (lack of CD8+ T-cell infiltration).
*   **Radiomic Correlation:** CT and PET radiomics have been correlated with **PD-L1 expression** levels and **Tumor Mutational Burden (TMB)**.
*   *Literature:* A landmark study in *The Lancet Oncology* (Sun et al.) demonstrated that a radiomic signature of CD8 cells could predict immunotherapy response better than standard biopsy in some cohorts.

#### D. Radiotherapy (Radioresistance)
*   **Hypoxia:** Hypoxic tumors are resistant to radiation.
*   **Correlation:** PET/CT radiomics (using tracers like FMISO or standard FDG) can identify sub-regions of the tumor that are hypoxic based on intensity and texture distribution, predicting local failure.

### 3. The Critical Caveat: "Consistent and Statistically Significant"
You asked if the literature demonstrates a *consistent* correlation. This is where the science is currently struggling.

While individual studies show high statistical significance (p < 0.05), the field suffers from a **reproducibility crisis**.

1.  **Lack of Standardization:** Radiomic features are highly sensitive to image acquisition parameters. A scan taken on a GE scanner may yield different texture values than one taken on a Siemens scanner, even for the same patient. This makes a "signature" found in one paper fail when applied to a different hospital's data.
2.  **Overfitting:** Many studies use small datasets (n < 200). They find a statistically significant correlation within their specific dataset, but the model fails to generalize to the outside world.
3.  **Segmentation Variability:** The correlation depends heavily on how the tumor is outlined (segmented). Manual vs. automated segmentation can alter the radiomic features, changing the correlation results.

### Summary
**Is there a correlation?**
**Yes.** Radiomics serves as a non-invasive surrogate for the underlying biological heterogeneity that drives resistance.

**Is it consistent and statistically significant in the literature?**
*   **Statistically Significant:** **Yes**, in the vast majority of published retrospective studies.
*   **Consistent:** **Not yet.** While the signal is real, the "signatures" (the specific combination of features) often vary between studies.

**Current Trend:** The field is moving toward **Deep Learning (CNNs)** and multi-center standardization (IBSI guidelines) to solve the consistency problem, aiming to create robust biomarkers that can predict resistance before treatment begins.